46例癫痫病患者临床治疗效果分析

Clinical Therapeutic Effect Analysis of 46 Patients with Epilepsy

目的分析德巴金联合利必通治疗癫痫病患者的临床疗效,探讨德巴金联合利必通在治疗癫痫病中的临床价值。方法随机抽选2014年1月1日—2015年6月30日在该院就诊并接受治疗的癫痫病患者共计92例,随机分为对照组和观察组,每组46例患者。为对照组患者予以德巴金治疗,对观察组患者提供德巴金联合利必通治疗,观察并比较两组患者经治疗后的疗效。结果经治疗观察组患者的总有效率为86.06%(40/46),对照组的总有效率为65.22%(30/46),观察组优于对照组,疗效显著。而不良反应方面观察组不良反应发生率26.09%(12/46)对照组不良反应发生率为30.43%(14/46),两组比较差异无统计学意义(P>0.05)。结论德巴金联合利必通对癫痫病的治疗能够获得较好疗效,值得临床推广。

Objective To discuss the clinical value of Debakin and Lamictal in the treatment of epilepsy via analyzing the clinical efficacy of combined medication of these two drugs in the treatment of the disease. Methods A total of 92 cases with epilepsy diagnosed and treated in our hospital from January 1, 2014 to June 30, 2015 were randomly selected and divided into the control group and the observation group with 46 cases in each. Patients in the control group were treated by Debakin, and those in the observation group were treated by combined medication of Debakin and Lamictal. The curative effects of two groups were observed and compared after treatment. Results The overall response rate was much higher in the observation group than that in the control group [86.06%（40/46） vs 65.22%（30/46）]. The incidence of adverse reactions was 26.09%（12/46）, 30.43%（14/46） in the observation group and control group respectively with no statistically significant difference（P〉0.05）. Conclusion Combined medication of Debakin and Lamictal has good curative effect in the treatment of epilepsy, which is worthy of clinical promotion.